Kalbe Farma Tbk.

Brief of Company Background

Founded in 1966, Kalbe Farma (Kalbe) is the largest publicly-listed pharmaceutical company in Southeast Asia.

Guided by a vision to become the country’s best global healthcare company and anchored in its core values encapsulated by “Panca Sradha,” Kalbe offers a comprehensive healthcare solution through its four key business divisions: prescription pharmaceuticals, consumer health, nutrition, and distribution & logistics. Within these divisions, Kalbe manages a diverse portfolio encompassing prescription medications, over-thecounter drugs, energy drinks, nutritional products, and medical devices, reinforced by a robust distribution network that serves over one million outlets across Indonesia’s vast archipelago.

On the international stage, Kalbe has established a strong presence in ASEAN countries, as well as regions spanning East and South Asia, the Middle East, and Africa. This solidifies Kalbe’s position as a prominent national pharmaceutical company with a competitive edge in the global export market.

In response to shifts in the healthcare industry, Kalbe has also strategically expanded its digital footprint in recent years by engaging in diverse e-commerce initiatives that cater to the rapidly expanding population of digitally-savvy consumers.

Kalbe’s business ventures are supported by bestin- class research and development capabilities, developed through strategic alliances with many international partners. The Company is deeply involved in cutting-edge areas such as drug delivery systems, cancer treatment, stem cell research, and biotechnology. These initiatives enable Kalbe to consistently introduce innovative products and services, keeping it at the forefront of innovation ahead of its competitors.

As of end 2023, Kalbe’s extensive healthcare ecosystem encompasses a network of 47 companies, including subsidiaries, joint ventures, and associates, all driven by a dedicated workforce of 16,795 employees. This collective effort has contributed to a substantial market capitalization of Rp74.5 trillion and an annual net sales of Rp30,449 billion.

Shareholder List

Management